Drug Trial Radar · NCT07594769
A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
May 11, 2026
Primary completion
Sep 1, 2026
Study completion Sep 1, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the bioequivalence of an alternative ODT formulation (ODT2) versus the approved ODT formulation of a CGRP receptor antagonist in healthy adult participants under fasting conditions.
Conditions
- Migraine
Interventions
ODT2 Test formulationDrug
Test Formulation
ODT Reference formulationDrug
Reference Formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of the test and reference formulationsTime frame: Pre-dose to 72 hours
- Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast) of the test and reference formulationsTime frame: Pre-dose to 72 hours
- Maximum observed plasma concentration (Cmax) of test and reference formulationsTime frame: Pre-dose to 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.